On Monday, Terns Pharmaceuticals Inc (NASDAQ: TERN) was -2.40% drop from the session before settling in for the closing price of $6.67. A 52-week range for TERN has been $3.26 – $11.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.00%. When this article was written, the company’s average yearly earnings per share was at -1.36%. With a float of $63.36 million, this company’s outstanding shares have now reached $64.58 million.
Considering the fact that the conglomerate employs 66 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 30.56%, operating margin of -8186.46%, and the pretax margin is -7233.74%.
Terns Pharmaceuticals Inc (TERN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Terns Pharmaceuticals Inc stocks. The insider ownership of Terns Pharmaceuticals Inc is 24.96%, while institutional ownership is 59.68%. The most recent insider transaction that took place on Sep 12 ’24, was worth 4,999,995. In this transaction Director of this company bought 476,190 shares at a rate of $10.50, taking the stock ownership to the 476,190 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Chief Financial Officer sold 10,000 for $11.00, making the entire transaction worth $110,000. This insider now owns 91,940 shares in total.
Terns Pharmaceuticals Inc (TERN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1.36% per share during the next fiscal year.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
You can see what Terns Pharmaceuticals Inc (TERN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 21.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Compared to the last year’s volume of 1.29 million, its volume of 1.61 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 2.06%. Additionally, its Average True Range was 0.48.
During the past 100 days, Terns Pharmaceuticals Inc’s (TERN) raw stochastic average was set at 2.59%, which indicates a significant increase from 1.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.01% in the past 14 days, which was lower than the 83.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.25, while its 200-day Moving Average is $7.03. Nevertheless, the first resistance level for the watch stands at $6.76 in the near term. At $7.01, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.15. If the price goes on to break the first support level at $6.37, it is likely to go to the next support level at $6.24. Should the price break the second support level, the third support level stands at $5.99.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Key Stats
There are 64,677K outstanding shares of the company, which has a market capitalization of 549.70 million. As of now, sales total 0 K while income totals -90,210 K. Its latest quarter income was 0 K while its last quarter net income were -22,740 K.
